SSTR2 and meningioma: 67.7% of meningiomas developed in female patients expressed somatostatin receptor SSTR-2/SSTR-2a subtype (95% CI: 59.7; 75.7) versus 77.4% of meningiomas in males (95% IC: 48.2; 100).